ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Clinical trials for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New approach aims to stop Graft-Versus-Host disease in young cancer patients
Disease control Recruiting nowThis study tests whether removing a specific type of immune cell (naive T cells) from donated stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body, causing long-term…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
Pre-Transplant fitness program aims to boost recovery in blood cancer patients
Disease control Recruiting nowThis study tests whether a prehabilitation program (exercise and nutrition support) before a stem cell transplant can improve quality of life and physical recovery in adults with blood cancer. About 110 participants will be randomly assigned to the program or standard care. The g…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated May 26, 2026 06:43 UTC
-
Donor cells take on viruses in transplant patients
Disease control Recruiting nowThis early-phase study tests whether specially trained white blood cells from a donor can safely control or clear cytomegalovirus (CMV) or adenovirus infections in people who have had a stem cell or solid organ transplant. About 20 participants will receive these virus-fighting c…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: EARLY_PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug cocktail aims to boost stem cell transplant success in elderly leukemia patients
Disease control Recruiting nowThis study tests a new drug combination called VABu given before a stem cell transplant in people aged 60 and older with acute myeloid leukemia (AML). The goal is to see if this approach can help control the disease and improve survival. About 20 participants will receive the VAB…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: PHASE2, PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 18, 2026 12:02 UTC